Replies to post #1040 on Bristol Myers Squibb (BMY)

[DewDiligence]

Mavacamten phase-3 succeeds in patients with obstructive HCM eligible for septal reduction therapy:

https://www.businesswire.com/news/home/20220215005925/en

Note: The above is a narrower indication than the one BMY is seeking in the existing NDA that has a 4/28/22 PDUFA date.